Horizon Therapeutics has awarded grants to help support 50 organizations around the world that are focused on improving the lives of people with rare disorders such as Batten disease. The grants were awarded through the company’s #RAREis Global Advocate Grant initiative, which launched last year with the aim…
News
Children with juvenile Batten disease frequently show abnormalities in eye tests, such as a bull’s-eye appearance in the macula — the center of the retina, at the back of the eye — and reduced electrical activity in light-sensing eye cells, according to a new study. The findings highlight the…
Theranexus has launched a global offering of around €4 million (about $4.5 million) to help fund the pivotal Phase 3 trial of the company’s investigational therapy Batten-1 for juvenile Batten disease. The Beyond Batten Disease Foundation (BBDF) acquired €1.15 million (about $1.3 million) in shares before the…
Researchers have identified new cellular roles for the CLN3 protein, the loss of which is the cause of juvenile Batten disease, or CLN3 disease. The loss of CLN3 in cell cultures leads to improper trafficking of enzymes needed for the function of lysosomes, the cellular compartments responsible for degrading…
Researchers have discovered a new naturally occurring nonhuman primate model of late-infantile Batten disease, or CLN2 disease. The primates, all of whom had a mutation in the CLN2 gene — the known cause of late-infantile Batten — also exhibited signs of the human condition including motor dysfunction, brain tissue atrophy, neuroinflammation,…
Researchers have developed a mouse model of juvenile Batten disease that better reflects the survival outcomes of human patients, according to a new study. While mice without the gene that carries instructions for the CLN3 protein recapitulate many juvenile Batten features, these mice have milder disease and a much…
Treatment for up to six months with Batten-1 — Theranexus’ novel therapy for juvenile Batten disease — reduced nerve cell death and stabilized patients’ motor symptoms. That’s according to preliminary results from an ongoing Phase 1/2 clinical trial testing the experimental therapy. The results will be presented at the…
A mini pig model could be an effective way to examine brain changes to track disease progression in late infantile Batten disease, a study suggests. In addition, measuring changes in the size of specific brain regions may help identify response to potential treatments, researchers note. “Miniswine present a…
From sharing stories on social media — using hashtags like #BattenDay2023 and #BattenAdvocatesForACure — to wearing something orange this June 9 to participating in a 5K fundraising challenge, supporters globally are poised to mark this year’s International Batten Disease Awareness Day. Observed annually, the June 9 Awareness Day calls attention…
Gene therapy was able to reduce the signs and symptoms of late infantile Batten disease in a mouse model carrying a common disease-causing mutation, a study shows. These findings support Regenxbio’s ongoing gene therapy program, which includes RGX-181, currently being tested as part of a single-patient study…
Recent Posts
- A mother’s dream for her child with Batten disease, written across heaven
- Low quality of life found for children with juvenile Batten and their parents
- Gut bacteria changes likely side effect, not driver, of CLN2 disease
- A moment in the sun shines a light on more than just the hard parts
- The part of rare disease care they don’t prepare you for
- Wearable device may aid Batten disease children with vision loss: Study
- Acknowledging the invisible cost of being a caregiver for Batten disease
- Many juvenile Batten disease patients face mental health issues: Study
- Our Batten disease journey carries on quietly, but with determination
- For our rare disease family, February is about love, advocacy, and unity